You are here

Femasys to Participate in Upcoming Investor Conferences

ATLANTA, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Femasys Inc., a developer of innovative medical solutions that improve women’s healthcare, today announced that Kathy Lee-Sepsick, Chief Executive Officer and President, will be participating in two upcoming investor conferences.

Stifel Healthcare Conference in New York City

  • Kathy Lee-Sepsick will present on Wednesday, November 14th at 10:15 am ET

Canaccord Genuity Medical Technologies & Diagnostics Forum in New York City

  • Kathy Lee-Sepsick will present on Thursday, November 15th at 10:00 am ET

About Femasys
Femasys is a privately held medical technology company committed to transforming women’s healthcare worldwide by developing and providing innovative gynecological solutions. Femasys’ flagship product, FemBloc® Permanent Contraceptive System, is based on the Company’s groundbreaking non-surgical platform technology. FemBloc utilizes a biopolymer and a catheter-based delivery system to permanently block the fallopian tubes and is delivered without the use of anesthesia or permanent implants, reducing risk to patients and lowering costs to the healthcare system. Femasys’ reproductive health portfolio also includes FemVue®, a product approved for sale in the U.S., Europe, Japan and Canada for the diagnosis of infertility, along with a pipeline of solutions designed to improve women’s healthcare in the physician’s office. *FemBloc Permanent Contraceptive System is not commercially available for sale. Femasys, FemBloc and FemVue are registered trademarks for Femasys Inc. All rights reserved.

For more information, please visit: www.Femasys.com.

CONTACTS:
Investor Relations
David Clair
Integrated Corporate Relations, Inc.
646-277-1266
david.clair@icrinc.com

Thursday, November 8, 2018 - 14:00

More Headlines

Zulresso May Alleviate Symptoms for Thousands of Women
Developed for Tumors Resistant to Other TKIs
New Drug Reduces Infection in Chemotherapy Patients
Daily Use of AHCC Supplement Could Support Immune System, Eliminate HPV
Unique Bio-Identical Hormone Therapy for Treatment of Hot Flashes
High-Tech “Nightwatch” is Capable of Detecting 85 Percent of Severe Night-Time Epileptic Seizures
Combination of Buprenorphine and Samidorphan Targets Opioid System Safely and Effectively
Prevents Harmful Effects of Chemotherapy